Farletuzumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight | ||
Farletuzumab is a humanized monoclonal antibody designed for the treatment of certain types of cancer. It specifically targets the folate receptor alpha, which is frequently overexpressed in epithelial cancers, including ovarian cancer, breast cancer, and lung cancer. Farletuzumab works by binding to this receptor and inhibiting the tumor's ability to grow and proliferate.
Mechanism of Action[edit | edit source]
Farletuzumab binds to the folate receptor alpha, a glycoprotein that is overexpressed in many epithelial cancers but has limited expression in normal tissues. This selective expression makes it an ideal target for therapeutic intervention. By binding to this receptor, farletuzumab can inhibit cancer cell growth and induce apoptosis (programmed cell death) directly, or it can recruit the immune system to attack the cancer cells through antibody-dependent cellular cytotoxicity (ADCC).
Clinical Trials[edit | edit source]
Farletuzumab has been evaluated in several clinical trials, primarily focusing on its effectiveness and safety in treating ovarian cancer. Early phase trials suggested that it might improve outcomes when used in combination with standard chemotherapy regimens. However, subsequent larger phase III trials have provided mixed results regarding its efficacy.
Development and Commercialization[edit | edit source]
The development of farletuzumab was conducted by Morphotek, Inc., a subsidiary of Eisai Co., Ltd. Despite the initial promise, the development has faced challenges due to the mixed results from clinical trials. The future of farletuzumab depends on the outcomes of ongoing research and potential further clinical trials designed to better define its role in cancer therapy.
Safety and Side Effects[edit | edit source]
As with many monoclonal antibodies, the use of farletuzumab can be associated with side effects, including but not limited to, infusion reactions, fatigue, nausea, and potential immunogenicity, where the body's immune system develops antibodies against the drug itself.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
